Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Yonago acta medicaOpen Access

Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

KKKoji Kawamura

Discussion

Loading...

Member takes

Overview

Review highlights challenges in transplant eligibility and donor selection for older patients, indicating evolving practices for hematological malignancies.

Key Points

  • Increased use of allogeneic transplantation has been observed in patients aged ≥ 70 with hematological malignancies, reflecting changing eligibility criteria.
  • Evidence shows that reduced-intensity conditioning is generally recommended for older patients, helping to reduce transplant-related complications.
  • Assessing eligibility also involves evaluating health status, comorbidities, and cognitive function to predict non-relapse mortality effectively.
  • Choosing the right donor is crucial, with matched related or younger unrelated donors preferred, though options are expanding with haploidentical donors.

Cite This Study

Koji Kawamura (2025) studied this question.

synapsesocial.com/papers/68c1b36054b1d3bfb60ea626https://doi.org/10.33160/yam.2025.08.001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic Value of Geriatric Characteristics in Allogeneic Haematopoietic Stem Cell Transplant Recipients Aged Over 60 Years2025
  2. 2[Application of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia--Review].2025
  3. 3Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.2025
  4. 4Outcomes after unrelated donor allogeneic hematopoietic cell transplantation in age ≥65 using post-transplant cyclophosphamide.2026
  5. 5Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation2024 · 5 citations